News

The company is investing ~US$32 million in the facility to keep up with expected demand based on current forecasts, including potential new opportunities. This expansion of more than

The interim analysis for the efficacy of the AZD1222 vaccine candidate was based on 11,636 volunteers accruing 131 symptomatic infections from the phase 3 trials in the UK

Sotorasib, which is claimed to be the first KRAS G12C inhibitor to enter the clinic, is being assessed in the wide clinical programme examining 10 combinations with global

The Transaction is subject to the satisfaction or waiver of customary conditions, including the receipt of all applicable regulatory and NEO Exchange Inc. (the “NEO Exchange”) approvals. Adelia

The phase 2 segment has been designed to assess the safety and immunogenicity of INO-4800 Covid-19 vaccine candidate to confirm the dose for the subsequent efficacy assessment as

These data are being presented today at the 62nd American Society for Hematology Annual meeting taking place virtually from December 5th – 8th. The oral presentation slides, which include follow-up

SY-2101 represents a strategic opportunity to leverage Syros’ expertise and capabilities to advance its growing footprint in hematologic disorders, with a targeted clinical-stage drug candidate that has the

Via its affiliates, the investor Sino Biopharmaceutical has invested around $500m in exchange for about 15% of the total equity interest of Sinovac LS. Earlier to the announcement

Aspartylglucosaminuria (AGU) is an inherited rare, progressively debilitating neurodegenerative lysosomal storage disorder. Currently there are no approved treatments to slow or cure AGU in patients living with this